Protalix BioTherapeutics and Brazil's Ministry of Health Enter Into Supply and Technology Transfer Agreement for UPLYSO(TM)

Protalix BioTherapeutics and Brazil's Ministry of Health Enter Into Supply and
Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) in Brazil

Exclusive License and Supply Agreement With Pfizer Amended to Facilitate the
Technology Transfer

CARMIEL, Israel, June 19, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has entered into a
supply and technology transfer agreement with Fundação Oswaldo Cruz (commonly
referred to as Fiocruz), an arm of the Brazilian Ministry of Health for
UPLYSO™ (alfataliglicerase), the Company's proprietary enzyme replacement
therapy for the treatment of Gaucher disease. Gaucher disease is a rare
lysosomal storage disorder that affects approximately 10,000 people worldwide.

The technology transfer is expected to take place during a seven-year term and
is intended to transfer to Fiocruz the capacity and skills required for the
Brazilian government to construct its own manufacturing facility, at its sole
expense, and to produce a sustainable, high quality, and cost effective supply
of UPLYSO.Under the agreement, Fiocruz has committed to purchase at least
approximately US$40 million worth of UPLYSO during the first two years of the
agreement. In subsequent years, Fiocruz is required to purchase at least
approximately US$40 million worth of UPLYSO per year.Additionally, Protalix
is not required to complete the final stage of the technology transfer until
Fiocruz purchases at least approximately US$280 million worth of UPLYSO.The
agreement may be extended for an additional five-year term, as needed, to
complete the technology transfer.All of the terms of the arrangement,
including the minimum annual purchases, will apply during the additional
term.

"We are excited to be working with the Brazilian government in its efforts to
provide UPLYSO to Gaucher patients in Brazil and to collaborate with Fiocruz
regarding our plant cell technology," said Dr. David Aviezer, Protalix
BioTherapeutics' President and Chief Executive Officer. "We are encouraged by
the recognition of our drug and our technology by both Fiocruz and Brazil's
Ministry of Health, and believe that this agreement will further establish a
reliable supply of treatment for patients living with Gaucher disease."

The technology transfer agreement becomes effective after the parties receive
approval of the agreement by the Brazilian National Institute of Industrial
Property, which is expected to occur in approximately one month. During the
technology transfer period, Fiocruz will apply for its own registration of
UPLYSO with the Brazilian National Health Surveillance Agency (ANVISA, Agencia
Nacional de Vigilancia Sanitaria) and continue to make the product
available.Once the technology transfer is complete, the government will be
the sole source of this important treatment option for Gaucher patients in
Brazil.

"It is an honor to announce this agreement with Protalix for the supply and
production of UPLYSO in Brazil," commented Dr. Alexandre Padilha, Brazil's
Minister of Health. "Through this collaboration, we are able to strengthen our
technological and industrial capabilities in the area of biologics
manufacturing and improve the health of Brazilian citizens who are impacted by
this rare disorder."

In March 2013, the Brazilian National Health Surveillance Agency (ANVISA,
Agencia Nacional de Vigilancia Sanitaria) granted regulatory approval to
Pfizer for UPLYSO which is indicated for the long-term enzyme replacement
therapy for adults with a confirmed diagnosis of Type I Gaucher disease.

To facilitate the arrangement with Fiocruz, the Company's commercialization
partner for UPLYSO, Pfizer Inc., amended its exclusive license and supply
agreement and returned commercialization rights in Brazil to the Company.In
consideration for the return of these rights, the Company will pay Pfizer a
maximum amount of approximately US$12.5 million from the Company's net profits
generated in Brazil per year of the agreement.During the transition of
commercial rights back to the Company, Pfizer will continue to support Gaucher
disease patients in Brazil who are being treated with UPLYSO.

The Company will pay a fee equal to 5% of the net proceeds generated in Brazil
to its agent for services provided in assisting the Company to complete the
agreement.

UPLYSO is marketed as ELELYSO^TM in the United States and Israel.

The Company's management will discuss certain terms and conditions of the
agreement during its previously scheduled analyst event on Thursday, June 20,
2013 at 8:00 AM EDT.The event audio and slide presentation will be webcast
live and archived on the Company's website for a 30-day period.The webcast
will be available at www.protalix.com on the Events Calendar page.The slides
will be available under the presentation tab on the Company's website after
the presentation.

Protalix BioTherapeutics Inc.

Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell based expression system, ProCellEx®.Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.Protalix's first
product manufactured by ProCellEx, taliglucerase alfa, was approved for
marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by
Israel's Ministry of Health in September 2012, by the Brazilian National
Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal
Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013,
and by the regulatory authorities of other countries.Marketing applications
for taliglucerase alfa have been filed in additional territories as
well.Protalix has partnered with Pfizer Inc. for the worldwide development
and commercialization of taliglucerase alfa, excluding Israel, where Protalix
retains full rights.Protalix's development pipeline also includes the
following product candidates: PRX-102, a modified version of the recombinant
human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a
pegylated recombinant human acetylcholinesterase in development for several
therapeutic and prophylactic indications, a biodefense program and an
organophosphate-based pesticide treatment program; an orally-delivered
glucocerebrosidase enzyme that is produced and encapsulated within carrot
cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant
cell version of etanercept (Enbrel®) for the treatment of certain immune
diseases such as rheumatoid arthritis, juvenile idiopathic arthritis,
ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.

Forward Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe-harbor provisions of the Private Securities Litigation Reform Act of
1995.The terms "anticipate," "believe," "estimate," "expect," "plan" and
"intend" and other words or phrases of similar import are intended to identify
forward-looking statements.These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made.These
statements are based on our current beliefs and expectations as to such future
outcomes.Drug discovery and development involve a high degree of
risk.Factors that might cause material differences include, among others:
risks related to the acceptance and use of UPLYSO by physicians, patients and
the Brazilian Ministry of Health; risks related to our and Fiocruz's ability
to market UPLYSO to the Brazilian Ministry of Health; our dependence on
performance by third party providers of services and supplies relating to the
commercialization of taliglucerase alfa in Brazil; the inherent risks and
uncertainties in developing drug platforms and products of the type we are
developing; the impact of development of competing therapies and/or
technologies by other companies and institutions; potential product liability
risks, and risks of securing adequate levels of product liability and other
necessary insurance coverage; and other factors described in our filings with
the U.S. Securities and Exchange Commission.The statements in this release
are valid only as of the date hereof and we disclaim any obligation to update
this information.

CONTACT: Investor Contact
        
         Marcy Beth Nanus
         The Trout Group, LLC
         646-378-2953
         MNanus@troutgroup.com
        
         Media Contact
        
         Kari Watson
         MacDougall Biomedical Communications
         781-235-3060
         kwatson@macbiocom.com
 
Press spacebar to pause and continue. Press esc to stop.